868247-72-7
Chemical Structure
Pam2CSK4
- CAS No.: 868247-72-7
- Formula:C65H126N10O12S
- Molecular Weight:1271.82
IUPAC Name: S-((R)-2,3-bis(palmitoyloxy)propyl)-L-cysteinyl-L-seryl-L-lysyl-L-lysyl-L-lysyl-L-lysine
InChIKey: LJUIOEFZFQRWJG-GHYFRYPYSA-N
SMILES: O=C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CCCCN)=O)[C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CSC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)=O)=O)=O
Biological Activity: Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pam2CSK4 | Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kulsantiwong P, et al. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264.7. Inflamm Res. 2017;66(10):843-853. [Content Brief]
- [2]. Parra-Izquierdo I, et al. The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton’s Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions. Front. Immunol.12:729951.McCarty OJT and Aslan JE (2021)
- [3]. Kaur A, Poonam, Patil MT, Mehta SK, Salunke DB. An efficient and scalable synthesis of potent TLR2 agonistic PAM2CSK4. RSC Adv. 2018 Mar 5;8(18):9587-9596.
- [4]. Maruyama A, et al. Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem Biophys Res Commun. 2015;457(3):445-450. [Content Brief]
- [5]. Shukla NM, et al. Recent Advances and Perspectives in Small-molecule TLR Ligands and Their Modulators. ACS Med Chem Lett. 2018;9(12):1156-1159. Published 2018 Dec 3. [Content Brief]
- [6]. Halliday A, et al. The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models. Parasit Vectors. 2016 Feb 20;9:96. [Content Brief]
Keywords
